Dimerix (DXB.AX) Aktsia Kursus

Dimerix Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Dimerix Ltd in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services as Dimerix Ltd. However, Dimerix Ltd stands out due to its unique offerings and strong market presence. Despite facing competition, Dimerix Ltd continues to solidify its position as a market leader through innovation, strategic partnerships, and consistent growth.

Dimerix Ltd is a renowned Australian biopharmaceutical company that specializes in the development and commercialization of innovative therapies. Established in [year], Dimerix has a strong history of cutting-edge research and collaboration with leading scientific institutions. The company's primary focus lies in developing novel treatments for unmet medical needs, particularly in the field of kidney disease and cancers. Dimerix's expertise lies in its proprietary drug development platform, enabling the identification and optimization of potential drug candidates. With a dedicated team of experts, Dimerix is committed to advancing scientific breakthroughs and improving the lives of patients worldwide.

Dimerix Ltd has achieved several significant milestones. The company successfully completed its Phase 2 clinical trials for DMX-200, its lead drug candidate. Dimerix also received Orphan Drug Designation from the FDA for DMX-200 in primary Focal Segmental Glomerulosclerosis (FSGS) patients. Additionally, the company secured important partnerships and collaborations with renowned organizations and experts in the field. Dimerix's commitment to innovation and clinical advancement has positioned the company as a leader in the biopharmaceutical industry.

Dimerix Ltd is primarily present in Australia.

Dimerix Ltd represents a set of values and a corporate philosophy that emphasize innovation, scientific excellence, and patient-centered healthcare solutions. With a focus on developing novel therapies for unmet medical needs, Dimerix is committed to enhancing the lives and treatment options for patients. Through collaboration, research, and the application of advanced technology, the company strives to deliver high-quality pharmaceutical products and make a positive impact in the healthcare industry. Dimerix Ltd's dedication to scientific rigor, customer satisfaction, and improving patient outcomes sets a strong foundation for its growth and success in the market.

5 analüütikut hindavad praegu Dimerix aktsiat: 4 soovitab osta, 1 hoida ja 0 müüa.

Dimerix Analüütikute kurssizihtpunktid 2026

Praeguse kursiga kaubeldakse Dimerix aktsiaga 0,14 EUR (0,22 AUD) juures.

Dimerix aktsia (DXB.AX) on noteeritud 1 börsil, sh: ASX (DXB.AX).

Dimerix Ltd is a global biotech company specialized in identifying and developing new therapeutics for serious diseases. The company utilizes an innovative strategy that uses G-Protein Coupled Receptors (GPCRs) as targets for drug development. Their business model focuses on developing both their own drug candidates and customized solutions for clients. They employ various platform technologies and tools to analyze the functioning of GPCRs and their interaction with other proteins in signaling pathways. Dimerix offers a range of molecular tools that can be used for identifying new drug candidates and validating targets. Their main products include specialized screening kits that modulate the GPCR signaling pathway and facilitate drug identification. These kits are sold to pharmaceutical and biotech companies as well as academic research institutions. Dimerix also provides customized services tailored to the needs of clients, ranging from identifying potential drug candidates to evaluating the efficacy and toxicity of existing drug candidates. These customized services are primarily sold to pharmaceutical and biotech companies involved in their own drug development. Another important aspect of Dimerix's business model is collaboration with other companies and research institutions. Dimerix works closely with partners to develop new drug candidates and target validation solutions. An example of such collaboration is the partnership with pharmaceutical company Merck KGaA to develop new immuno-oncology drugs. Dimerix has a strong financial position and has successfully completed numerous financing rounds to expand its product range and services. The company also has a strong intellectual property position secured through patents and licensing agreements. In summary, Dimerix's business model is focused on identifying and developing novel drugs for serious diseases. The company utilizes innovative platform technologies and tools to analyze GPCR signaling pathways and identify new targets. Dimerix offers both their own products and customized services to support clients in drug development. With close collaboration with partners and a strong financial position, the company is well positioned to advance its mission and provide innovative solutions for patients.

Dimerix käive on 4,35 M AUD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

Dimerix kasum on −29,81 M AUD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Dimerix jaoks on praegu −4,43. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Dimerix aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Dimerix jaoks on praegu 30,36. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Dimerix aktsia jaoks.

Eulpooli kvaliteedinäitaja Dimerix jaoks on 4/10.

Dimerix ISIN on AU000000DXB7. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Dimerix ticker on DXB.AX. Ticker-sümbol kasutatakse Dimerix aktsiate kauplemiseks börsil.